ELSEVIER

International Journal of Antimicrobial Agents 11 (1999) 313–315

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

Author index

Volume 11 (1999)

Amsden, G.W., Pharmacological considerations in the emergence of resistance **11**, S7
Andriole, V.T., When to do culture in urinary tract infections **11**, 253
Araj, G.F., R.S. Talhouk, C.J. Simaan and M.J. Maasad, Discrepancies between *mec*A PCR and conventional tests used for detection of methicillin resistant *Staphylococcus aureus* **11**, 47
Arakawa, S., T. Matsui, K. Gohji, H. Okada and S. Kamidono, Prostatitis—the Japanese viewpoint **11**, 201
Araujo, F.G., see Khan, A.A. **11**, 121

Babić, D., see Nikolić, T. **11**, 145
Been-Tiktak, A.M.M., C.A.B. Boucher, F. Brun-Vezinet, V. Joly, J.W. Mulder, J. Jost, D.A. Cooper, M. Moroni, J.M. Gatell, S. Staszewski, R. Colebunders, G.J. Stewart, D.A. Hawkins, M.A. Johnson, J.M. Parkin, D.H. Kennedy, J.F. Hoy and J.C.C. Borleffs, Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial **11**, 13
Begovac, J., see Schönwald, S. **11**, 309
Beier, M.T., Management of urinary tract infections in the nursing home elderly: a proposed algorithmic approach **11**, 275
Belič, A., see Beovič, B. **11**, 81
Beovič, B., A. Mrhar, R. Karba, T. Župančič, Iztok Grabnar, A. Belič and M. Marolt-Gomišček, Influence of fever on the pharmacokinetics of ciprofloxacin **11**, 81
Blondeau, J.M., N. Castanedo, O. Gonzalez, R. Mendina and E. Silveira, In vitro evaluation of G1: a novel antimicrobial compound **11**, 163
Bobić, B., see Nikolić, T. **11**, 145
Borleffs, J.C.C., see Been-Tiktak, A.M.M. **11**, 13
Borner, K., H. Hartwig, S. Leitzke, H. Hahn, R.H. Müller and S. Ehlers, HPLC determination of clofazimine in tissues and serum of mice after intravenous administration of nanocrystalline or liposomal formulations **11**, 75
Boucher, C.A.B., see Been-Tiktak, A.M.M. **11**, 13
Bouza, E., Antibiotic resistance and therapeutic options in lower respiratory tract infections **11**, S3
Bow, L., see Onyeji, C.O. **11**, 31
Bradley, J.S., J. Garau, H. Lode, K.V.I. Rolston, S.E. Wilson and J.P. Quinn, Carbapenems in clinical practice: a guide to their use in serious infection **11**, 93
Brun-Vezinet, F., see Been-Tiktak, A.M.M. **11**, 13

Castanedo, N., see Blondeau, J.M. **11**, 163
Chambers, S.T., B.A. Peddie, K. Randall and M. Lever, Inhibitors of bacterial growth in urine: what is the role of betaines? **11**, 293
Chang, H.-J., see Chang, S.-C. **11**, 23
Chang, S.-C., H.-J. Chang and M.-S. Lai, Antibiotic usage in primary care units in Taiwan **11**, 23
Chautemps, R., see Zanetti, G. **11**, 107
Choi, D.H., S. Shin and I.K. Park, Characterization of antimicrobial agents extracted from *Asterina pectinifera* **11**, 65
Chow, J.W. and V.L. Yu, Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary **11**, 7
Colebunders, R., see Been-Tiktak, A.M.M. **11**, 13
Cooper, D.A., see Been-Tiktak, A.M.M. **11**, 13

Dabernat, H., The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible *Haemophilus influenzae* in comparison with ofloxacin, ciprofloxacin and sparfloxacin **11**, 139
Djurković-Djaković, O., see Nikolić, T. **11**, 145
Dubrava, M., see Krcmery, S. **11**, 289

Ehlers, S., see Borner, K. **11**, 75
Eoconomou, E., see Giamarellou-Bourboulis, E.J. **11**, 115

Fotopoulou, N., S. Tsiplakou, A.N. Maniatis, A. Pangali, G. Kouppari, N.J. Legakis and P.T. Tassios, Gradual increase in the minimum inhibitory concentration of penicillin among both susceptible and resistant *Streptococcus pneumoniae* isolates from Greek children during 1995–1997 **11**, 53
Fukushima, K., see Hirasawa, M. **11**, 151
Fünfstück, R., M. Wolfram, J. Gerth, K. Schubert, E. Straube and G. Stein, The influence of ofloxacin (Tarivid®) on the parasite–host inter-relationship in patients with chronic urinary tract infection **11**, 297

Ganeo, M., see Zanetti, G. **11**, 107
Garau, J., see Bradley, J.S. **11**, 93
Gatell, J.M., see Been-Tiktak, A.M.M. **11**, 13
Gerth, J., see Fünfstück, R. **11**, 297
Giamarellou-Bourboulis, E.J., J. Perdios, M. Lelekis, E. Eoconomou, P. Tsouroulas and H. Giamarellou, Impact of cefuroxime administration on endotoxin (LPS) and tumour necrosis factor-α (TNFα) blood levels in patients suffering from acute pyelonephritis: a preliminary report **11**, 115
Giamarellou, H., see Giamarellou-Bourboulis, E.J. **11**, 115
Glauser, M., see Zanetti, G. **11**, 107
Gohji, K., see Arakawa, S. **11**, 201
Gonzalez, O., see Blondeau, J.M. **11**, 163
Goto, T., Y. Nakame, M. Nishida and Y. Ohi, Bacterial biofilms and catheters in experimental urinary tract infection **11**, 227
Goto, Y., K. Hiramatsu and M. Nasu, Improved efficacy with nonsimultaneous administration of netilmicin and minocycline against methicillin–resistant *Staphylococcus aureus* in in vitro and in vivo models **11**, 39
Grimm, H., Conclusion **11**, S33

PII: S0924-8579(99)00066-7

Gupta, K., T.M. Hooton, C.L. Wobbe and W.E. Stamm, The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women **11**, 305

Hahn, H., see Borner, K. **11**, 75
Harbarth, S.J., see Zanetti, G. **11**, 107
Hartwig, H., see Borner, K. **11**, 75
Hawkins, D.A., see Been-Tiktak, A.M.M. **11**, 13
Higashi, N., see Shimizu, T. **11**, 69
Hiramatsu, K., see Goto, Y. **11**, 39
Hirasawa, M., N. Shouji, T. Neta, K. Fukushima and K. Takada, Three kinds of antibacterial substances from *Lentinus edodes* (Berk.) Sing. (Shiitake, an edible mushroom) **11**, 151
Hirose, T., see Tsukamoto, T. **11**, 233
Hooton, T.M., Practice guidelines for urinary tract infection in the era of managed care **11**, 241
Hooton, T.M., see Gupta, K. **11**, 305
Hotta, H., see Tsukamoto, T. **11**, 233
Hoy, J.F., see Been-Tiktak, A.M.M. **11**, 13

Ishihara, S., see Kawada, Y. **11**, 185
Itoh, N., see Tsukamoto, T. **11**, 233
Iztok Grabnar, see Beovič, B. **11**, 81

Johnson, M.A., see Been-Tiktak, A.M.M. **11**, 13
Joly, V., see Been-Tiktak, A.M.M. **11**, 13
Jost, J., see Been-Tiktak, A.M.M. **11**, 13

Kamidono, S., see Arakawa, S. **11**, 201
Karba, R., see Beovič, B. **11**, 81
Kawada, Y. and S. Ishihara, Adequacy of the new guidelines on clinical evaluation of drug efficacy in acute uncomplicated cystitis **11**, 185
Kennedy, D.H., see Been-Tiktak, A.M.M. **11**, 13
Khan, A.A., T.R. Slifer, F.G. Araujo and J.S. Remington, Effect of clarithromycin and azithromycin on production of cytokines by human monocytes **11**, 121
Kouppari, G., see Fotopoulou, N. **11**, 53
Krcmery, S. and K.G. Naber, Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections **11**, 133
Krcmery, S., M. Dubrava and V. Krcmery, Jr., Fungal urinary tract infections in patients at risk **11**, 289
Krcmery, V., Jr., see Krcmery, S. **11**, 289
Kumamoto, Y., see Tsukamoto, T. **11**, 233
Kumazawa, J., see Matsumoto, T. **11**, 269
Kunin, C.M., Guidelines and evaluation of new anti-infective drugs for treatment of urinary tract infections **11**, 197

Lai, M.-S., see Chang, S.-C. **11**, 23
Lange, J., see Zanetti, G. **11**, 107
Legakis, N.J., see Fotopoulou, N. **11**, 53
Leitzke, S., see Borner, K. **11**, 75
Lelekis, M., see Giamarellou-Bourboulis, E.J. **11**, 115
Lever, M., see Chambers, S.T. **11**, 293
Lew, D., see Zanetti, G. **11**, 107
Lode, H., see Bradley, J.S. **11**, 93
Ludwig, M., see Weidner, W. **11**, 257

Maasad, M.J., see Araj, G.F. **11**, 47
Majtánová, Ľ., see Majtán, V. **11**, 59
Majtán, V. and Ľ. Majtánová, The effect of new disinfectant substances on the metabolism of *Enterobacter cloacae* **11**, 59
Maniatis, A.N., see Fotopoulou, N. **11**, 53
Marolt-Gomiščck, M., see Beovič, B. **11**, 81
Matsui, T., see Arakawa, S. **11**, 201
Matsukawa, M., see Tsukamoto, T. **11**, 233
Matsumoto, T. and J. Kumazawa, Urinary tract infection in geriatric patients **11**, 269
Mendina, R., see Blondeau, J.M. **11**, 163
Mevius, D.J., M.J.W. Sprenger and H.C. Wegener, EU conference 'The Microbial Threat' **11**, 101
Morel, P., see Zanetti, G. **11**, 107
Moroni, M., see Been-Tiktak, A.M.M. **11**, 13
Mosimann, F., see Zanetti, G. **11**, 107
Mrhar, A., see Beovič, B. **11**, 81
Mulder, J.W., see Been-Tiktak, A.M.M. **11**, 13
Müller, R.H., see Borner, K. **11**, 75

Naber, K.G., Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections **11**, 189
Naber, K.G., see Krcmery, S. **11**, 133
Nakame, Y., see Goto, T. **11**, 227
Nasu, M., see Goto, Y. **11**, 39
Neta, T., see Hirasawa, M. **11**, 151
Nicolau, D.P., P.R. Tessier and C.H. Nightingale, Beneficial effect of combination antiplatelet therapy on the development of experimental *Staphylococcus aureus* endocarditis **11**, 159
Nicolau, D.P., see Onyeji, C.O. **11**, 31
Nicolle, L.E., Urinary infections in the elderly: symptomatic or asymptomatic? **11**, 265
Nightingale, C.H., see Nicolau, D.P. **11**, 159
Nightingale, C.H., see Onyeji, C.O. **11**, 31
Nikolić, A., see Nikolić, T. **11**, 145
Nikolić, T., O. Djurković-Djaković, B. Bobić, A. Nikolić and D. Babić, Treatment protocol determines the efficacy of clindamycin in acute murine toxoplasmosis **11**, 145
Nishida, M., see Goto, T. **11**, 227
Norrby, S.R., How adequate are the new guidelines on clinical evaluation of bacteriological outcome in uncomplicated UTI? **11**, 183

Ohi, Y., see Goto, T. **11**, 227
Okada, H., see Arakawa, S. **11**, 201
Onyeji, C.O., D.P. Nicolau, C.H. Nightingale and L. Bow, Interferon-γ effects on activities of gentamicin and vancomycin against *Enterococcus faecalis* resistant to the drugs: an in vitro study with human neutrophils **11**, 31

Pangali, A., see Fotopoulou, N. **11**, 53
Park, I.K., see Choi, D.H. **11**, 65
Parkin, J.M., see Been-Tiktak, A.M.M. **11**, 13
Peddie, B.A., see Chambers, S.T. **11**, 293
Perdios, J., see Giamarellou-Bourboulis, E.J. **11**, 115

Quinn, J.P., see Bradley, J.S. **11**, 93

Randall, K., see Chambers, S.T. **11**, 293
Rau, W., see Weidner, W. **11**, 257
Reid, G., Biofilms in infectious disease and on medical devices **11**, 223
Remington, J.S., see Khan, A.A. **11**, 121
Retsema, J.A., Susceptibility and resistance emergence studies with macrolides **11**, S15
Rolston, K.V.I., see Bradley, J.S. **11**, 93
Rosenberg, M., Pharmacoeconomics of treating uncomplicated urinary tract infections **11**, 247

Sano, C., see Shimizu, T. **11**, 69
Sano, M., see Tsukamoto, T. **11**, 233
Sato, K., see Shimizu, T. **11**, 69
Schaeffer, A.J., Prostatitis: US perspective **11**, 205
Schönwald, S., J. Begovac and V. Skerk, Urinary tract infections in HIV disease **11**, 309
Schubert, K., see Fünfstück, R. **11**, 297

Sefton, A.M., Macrolides and changes in the oral flora **11**, S23
Shibata, H., see Shimizu, T. **11**, 69
Shimizu, T., H. Tomioka, K. Sato, C. Sano, Y. Yamada, H. Shibata and N. Higashi, Effects of Yokuinin on the therapeutic efficacy of a new benzoxazinorifamycin KRM-1648 against *Mycobacterium avium* infection **11**, 69
Shin, S., see Choi, D.H. **11**, 65
Shouji, N., see Hirasawa, M. **11**, 151
Silveira, E., see Blondeau, J.M. **11**, 163
Simaan, C.J., see Araj, G.F. **11**, 47
Skerk, V., see Schönwald, S. **11**, 309
Slifer, T.R., see Khan, A.A. **11**, 121
Sobel, J.D., Management of asymptomatic candiduria **11**, 285
Sprenger, M.J.W., see Mevius, D.J. **11**, 101
Stamm, W.E., see Gupta, K. **11**, 305
Staszewski, S., see Been-Tiktak, A.M.M. **11**, 13
Stein, G., see Fünfstück, R. **11**, 297
Stewart, G.J., see Been-Tiktak, A.M.M. **11**, 13
Straube, E., see Fünfstück, R. **11**, 297

Takada, K., see Hirasawa, M. **11**, 151
Takahashi, S., see Tsukamoto, T. **11**, 233
Talhouk, R.S., see Araj, G.F. **11**, 47
Tassios, P.T., see Fotopoulou, N. **11**, 53
Tessier, P.R., see Nicolau, D.P. **11**, 159
Tomioka, H., see Shimizu, T. **11**, 69
Trampuz, A., see Zanetti, G. **11**, 107
Tsiplakou, S., see Fotopoulou, N. **11**, 53
Tsouroulas, P., see Giamarellou-Bourboulis, E.J. **11**, 115
Tsukamoto, T., M. Matsukawa, M. Sano, S. Takahashi, H. Hotta, N. Itoh, T. Hirose and Y. Kumamoto, Biofilm in complicated urinary tract infection **11**, 233

Wegener, H.C., see Mevius, D.J. **11**, 101
Weidner, W., M. Ludwig, B. Weimar and W. Rau, Rational diagnostic steps in acute pyelonephritis with special reference to ultrasonography and computed tomography scan **11**, 257
Weimar, B., see Weidner, W. **11**, 257
Williams, J.D., Introduction **11**, S1
Wilson, S.E., see Bradley, J.S. **11**, 93
Wobbe, C.L., see Gupta, K. **11**, 305
Wolfram, M., see Fünfstück, R. **11**, 297

Yamada, Y., see Shimizu, T. **11**, 69
Yu, V.L., see Chow, J.W. **11**, 7

Zanetti, G., S.J. Harbarth, A. Trampuz, M. Ganeo, F. Mosimann, R. Chautemps, P. Morel, D. Lew, W. Zimmerli, J. Lange and M. Glauser, Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections **11**, 107
Zimmerli, W., see Zanetti, G. **11**, 107
Župančič, T., see Beovič, B. **11**, 81